Drugmaker’s total revenues increased by 41% last year with help from $4bn Covid jab income
AstraZeneca forecast higher 2022 sales and lifted its annual dividend for the first time in a decade after beating fourth-quarter profit expectations, but warned the boost from its Covid-19 products would decline.
The Anglo-Swedish drugmaker made almost $4bn (£2.9bn) from its Vaxzevria Covid jab last year, including more than $1bn from Europe and $2.3bn from emerging markets. The jab has not yet been approved by US regulators.
